St. Jude has hope for ICDs
This article was originally published in The Gray Sheet
Executive Summary
The global ICD market in the second quarter "was flat to up slightly" compared with the same prior-year period, CFO John Heinmiller says during a July 19 earnings call. Last quarter, St. Jude forecasted that the market for ICDs worldwide would grow in the range of 5%-7% in Q2, with 11%-13% accelerated growth in the second half of the year (1"The Gray Sheet" April 24, 2006, p. 8). CEO Dan Starks remains confident that the U.S. ICD market will rebound "to support at least low double-digit growth on a global basis;" however, he now projects that this will not occur until 2007. St. Jude still raked in $278 mil. in ICD sales, an increase of 14% over the same period a year ago. The firm concludes it gained 0.5%-1% of ICD market share during the quarter, although Boston Scientific and Medtronic have yet to report their results. Nonetheless, the company down-adjusted its full-year guidance for global ICD revenue...
You may also be interested in...
St. Jude Drafts Three-Pronged Plan To Regain ICD Share, Misses Q1 Estimates
St. Jude Medical will launch new ICDs, open new accounts and hire sales people in the hopes of taking share back from on-the-mend ICD manufacturer Boston Scientific/Guidant
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.